The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

A Food and Drug Administration vaccine advisory committee meeting scheduled for March to select the strains to be included in ...

The latest meeting of the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...

The FDA canceled a meeting of vaccine advisors scheduled for next month to decide the composition of next season's influenza ...

NHS England said the ‘potential’ introduction of a varicella vaccine could be launched in January 2026, subject to ‘final ...

Preliminary results from a phase 3 study of the MenABCWY vaccine – which covers all five meningococcal strains in one go as an alternative to separate vaccinations – showed that it was at ...